Update from Biogen
In a community statement and press release, Biogen shared about the initiation of the BRAVE study, a global Phase 3 study evaluating the effects and safety of omaveloxolone in children with Friedreich ataxia (FA).
It is now open for enrollment at the Children’s Hospital of the King’s Daughter in Norfolk, VA. The study team is recruiting participants with a genetically confirmed FA diagnosis between the ages of 2-15 years. Participants must have no evidence of clinically significant heart disease and meet other study-specified eligibility criteria.
There are additional sites planned for this study both within and outside of the United States. FARA will continue to update the community as additional sites open.
Click below to read the full community statement from Biogen.
Anyone considering participating in a clinical trial should discuss the matter with their physician. FARA does not endorse or recommend any particular studies.
